Evidence Hub

Fatal cerebral scedosporiosis in a liver transplant recipient: Diagnostic pitfalls and antifungal resistance

Panda JP, Sunavala A, Narula S, Nagral A, Tandan S

Medical mycology case reports, 2026

Abstract

Scedosporium boydii causes lethal central nervous system (CNS) disease in transplant recipients and is intrinsically resistant to amphotericin B. A 54-year-old living-donor liver transplant recipient re-admitted (Day 0) with fever and diarrhoea, rapidly deteriorated neurologically, and developed ventriculitis with hydrocephalus. Liquid culture yielded a floating "fungal ball" by Day +8. Microscopy suggested Scedosporium/Lomentospora spp, MALDI-TOF, and ITS sequencing confirmed S. boydii. Amphotericin B MIC was 4.0 μg/mL; voriconazole MIC 0.03 μg/mL. Despite IV voriconazole (with intraventricular caspofungin) and neurosurgery, the patient died of complications. Early molecular identification and prompt switch from amphotericin B to azole-based therapy are critical in post-transplant CNS scedosporiosis.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free